The collaboration leverages uBriGene’s LVV Turbo platform for GMP lentiviral vector manufacturing and regulatory support.

Often diagnosed when surgery is no longer an option, pancreatic cancer is one of the most difficult cancers to treat and has ...

A key question for ESO-T01 and other in vivo candidates will be the durability of their cancer eradication. While the ...

The U.S. Food & Drug Administration (FDA) recently removed its Risk Evaluation and Mitigation Strategies (REMS) designation from CAR T immunotherapies. REMS is occasionally applied to drugs with ...

Concurrent statin therapy was associated with significantly improved survival outcomes and reduced neurotoxicity in patients ...

The consistency of results across racial groups suggests that, within the controlled setting of clinical trials, ...

The CAR-T Cellular Team at Children’s Hospital of The King’s Daughters is making it easier for children — and their families — to receive hard cancer treatments closer to home.

A new CAR T-cell therapy attacks supportive cells in the tumor microenvironment that bear the surface protein, uPAR.

Often diagnosed when surgery is no longer an option, pancreatic cancer is one of the most difficult cancers to treat and has ...

CAR T-cell therapy shows promise for SCLC, but significant barriers, such as tumor heterogeneity and immunosuppression, must be addressed. Identifying tumor-selective antigens like CDH17, GD2, and ...

CAR T-cell therapy is a personalized treatment that uses a patient’s own immune cells to fight cancer, making it effective but unsuitable for mass production, which increases the cost. The complex ...